OrganoTherapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

OrganoTherapeutics is a preclinical-stage biotech leveraging human iPSC-derived midbrain organoids to model Parkinson's Disease and other brain disorders. Its core platform generates patient-specific 3D brain models, including assembloids and microglia-enriched systems, which are used for drug testing and research services. The company integrates high-content imaging and RNA-seq data into a proprietary PD Knowledge Graph to enhance target discovery and validation, positioning itself at the intersection of advanced organoid technology and computational biology.

Parkinson's DiseaseNeuroscienceRare Disease

Technology Platform

Proprietary platform for generating human iPSC-derived midbrain organoids, assembloids (e.g., midbrain-striatum), and microglia/vascular-enriched systems. Integrated with a proprietary PD Knowledge Graph (PD-KG) that applies AI-driven algorithms to analyze high-content imaging and RNA-seq data for target discovery.

Opportunities

The high failure rate of neurotherapeutics in clinical trials, driven by poor animal model predictivity, creates strong demand for human-relevant models like organoids.

The large and growing Parkinson's Disease market, with no disease-modifying therapies, offers a direct and urgent application.

The platform's flexibility allows for expansion into other neurodegenerative and rare neurological diseases.

Risk Factors

Organoid technology faces challenges in standardization, scalability, and full physiological maturation.

Commercial adoption requires proving predictive clinical translation to risk-averse pharma partners.

As a young, private company, it is dependent on external funding and operates in a increasingly competitive market for advanced preclinical models.

Competitive Landscape

Competition includes other specialized organoid companies (e.g., StemoniX, Neurix), academic spin-offs, and large CROs investing in complex in vitro models. Differentiation hinges on OrganoTherapeutics' specific focus on midbrain/PD pathology, its advanced assembloid systems, and its integrated AI-driven PD Knowledge Graph for data analysis and insight generation.

More companies in Europe - Other →